Predictors of cancer disease progression improve patient selection for metastasis-directed therapy

December 10, 2012

December 10, 2012, New York, NY - Tumor metastasis, the ability of cancer cells to migrate from their tissue of origin and colonize elsewhere in the body, accounts for over 90% of cancer deaths. When patients die from cancer, it is usually caused by distant metastases established by malignant cells that split off from the primary cancer and began growing in new settings.

Scientists from the Ludwig Center at the University of Chicago hypothesized over 15 years ago that an intermediate state of tumor spread or metastasis exists between patients with extensive metastasis and patients whose disease stays confined to one local tumor with no spread. The scientists termed this intermediate state oligometastasis or metastasis limited in number and location. They then demonstrated that some patients with oligometastasis can be cured with therapies - including surgery and radiotherapy - that are directed locally at the metastasis.

In a paper published December 10 in PLOS ONE, the Ludwig investigators led by Dr. Ralph Weichselbaum in collaboration with Dr. Yves Lussier at the University of Illinois, took their research a step further. They analyzed patients with lung metastasis who underwent surgical resection with curative intent.

What they found was that some patients were cured, some developed rapid metastasis, and some developed metastasis at a very slow rate of progression. They then asked themselves what accounted for these radical differences in patient outcomes.

The answer: microRNAs or small molecules that suppress gene expression or protein synthesis. The investigators had pinpointed the culprit. They identified the microRNAs associated with oligometastatic progression and then found that these microRNAs differ from those associated with patients who developed widespread metastatic disease.

The microRNAs associated with oligometastasis have tumor suppressor characteristics that differ from microRNAs associated with patients who developed widespread metastatic disease. The results demonstrate a biological basis for oligometastasis and a potential for using microRNA expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment.

"With these findings, we are now able to use microRNA expression to characterize oligometastasis and ultimately better select patients with tumor metastasis for curative interventions," said study author Ralph Weichselbaum, MD, director of the Ludwig Center for Metastasis Research at the University of Chicago. "Also understanding the molecular basis of tumor metastasis will allow for the targeting of specific biological processes to treat patients with more advanced tumor spread."
-end-
This work was supported in part by the Ludwig Center for Metastasis Research Grant, the Center for Radiation Therapy, the Chicago Tumor Institute, the Ludwig Foundation for Cancer Research, Mr. and Mrs. Vincent Foglia and the Foglia Foundation, Lung Cancer Research Foundation, the Cancer Research Foundation and the following NIH Grants: K22 LM008308-04, 5UL1RR024999-04, University of Chicago Comprehensive Cancer Center (5P30CA014599-35), the University of Illinois Cancer Center, and the University of Illinois Center for Clinical and Translational Science (UL1RR029879).

About the Ludwig Institute for Cancer Research

The Ludwig Institute is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research. http://www.licr.org</p>

For further information please contact Rachel Steinhardt, rsteinhardt@licr.org or +1-212-450-1582.

Ludwig Institute for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.